A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A

  • Nature. 1996 Jul 25;382(6589):319-24. doi: 10.1038/382319a0.
X J Yang  1 ,  V V Ogryzko ,  J Nishikawa ,  B H Howard ,  Y Nakatani
Affiliations
  • 1. Laboratory of Molecular Growth Regulation, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892-2753, USA.
PMID: 8684459 DOI: 10.1038/382319a0
Abstract

The adenoviral oncoprotein E1A induces progression through the cell cycle by binding to the products of the p300/CBP and retinoblastoma gene families. A new cellular p300/CBP-associated factor (P/CAF) having intrinsic histone acetylase activity has been identified that competes with E1A. Exogenous expression of P/CAF in HeLa cells inhibits cell-cycle progression and counteracts the mitogenic activity of E1A. E1A disturbs the normal cellular interaction between p300/CBP and its associated histone acetylase.